Most S. Typhi vaccines carry deletion mutations associated with systemic dissemination, such as phoPQ, htrA, and ssaV, with no bacteremia observed during vaccination, indicating that the protection would theoretically depend largely on local immune induction sites.9 Therefore, we propose that a properly attenuated S. Typhimurium strain could also be used as a live typhoid vaccine and as a vaccine vector for human use. This evidence concerns the gene HTRA1 and bacterial infectious disease with sepsis.